VIDEO: Combination of BTK inhibitor with venetoclax shows promise in mantle cell lymphoma

In this video, Stephen M. Ansell, MD, PhD, discusses primary analysis results from the phase 3 Sympatico study.
The results, presented at ASH Annual Meeting and Exposition, showed a benefit in combining a BTK and BCL-2 inhibitor for relapsed/refractory mantle cell lymphoma, Ansell, professor of medicine in the department of hematology at Mayo Clinic, Minnesota, said.
The addition of venetoclax (Venclexta; AbbVie, Genentech) to ibrutinib (Imbruvica; Janssen, Pharmacyclics) showed benefit over ibrutinib and placebo alone, Ansell said.
“That’s a study with pretty substantial follow-up showing

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart